Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625000579493
Ethics application status
Approved
Date submitted
9/05/2025
Date registered
4/06/2025
Date last updated
4/06/2025
Date data sharing statement initially provided
4/06/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
The NIKI-C Study - A study of plasma pharmacokinetics of nebulized ketamine in post cardiac surgery patients.
Query!
Scientific title
A study of plasma pharmacokinetics of nebulized ketamine in post cardiac surgery patients in intensive care unit: A phase 2 single site, prospective, interventional, open-label pharmacokinetic study.
Query!
Secondary ID [1]
314304
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
NIKI-C Study
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Post-operative intensive care.
337252
0
Query!
Intensive Care Cardiac Surgery
337253
0
Query!
Condition category
Condition code
Anaesthesiology
333656
333656
0
0
Query!
Pain management
Query!
Cardiovascular
333968
333968
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This is a single site study, evaluating the pharmacokinetics (PK) of a single dose of nebulized ketamine in post cardiac surgery patients in the intensive care unit (ICU). The study also aims to define the optimal dosing regimens to inform future clinical trials.
Design and setting:
A minimum 20 post-operative cardiac surgery patients in the ICU that meet the inclusion criteria and none of the exclusion criteria will be recruited. In addition to standard analgesia and sedation prescribed by the treating clinician, each patient will receive nebulized ketamine 0.75mg/kg ideal body weight (IBW).
Consent
Patients must be able to consent for themselves in order to be eligible for the study. Patients are admitted to the ICU in the later part of the day and extubated later in the evening. The day following surgery patients will be assessed for suitability. Eligible patients will be approached by the Principal Investigator. In consultation with the treating team patients will be assessed for competence prior to approaching for consent.
Intervention
All patients continue to receive standard of care analgesia (oral, intravenous or epidural) as prescribed by the treating team.
A vibrating mesh nebuliser with mouthpiece and exhalation filter will be used to administer the ketamine. The exhalation filter on the nebulizer expiratory port will eliminate the risk of environmental contamination for those present. patients will be shown the nebulizer and given detailed instructions and demonstration regarding the use.
For patients on low flow (FiO2 < 0.4) or no oxygen the bacterial filter applied to the exhalation port will reduce fugitive emissions.
For patients on high flow nasal cannula (FiO2 < 0.4) the vibrating mesh nebulizer will be inserted in the circuit on the dry side of the humidifier as per current practice. the patient will be requested to wear a surgical mask to cover their mouth and prevent fugitive emissions.
Ketamine 0.75mg/kg (based on IBW) rounded to the nearest 5kg will be instilled in the nebulizer chamber to make up to a total of 3mL volume. Nebulization will continue until there is no visible mist.
Biological Samples
8 blood samples (3mL each) will be collected into heparinised tubes over two hours (T=0, T+5, +10, +15, +30, +60, +90, +120 minutes) via an existing arterial or central line.
A urine creatinine will be performed from time dosing commences until the end of the two hour sampling period. A 1 mL aliquot of urine from the total sample will be retained to determine renal excretion of the study drug.
Monitoring Fidelity
The qualified research team who are familiar with the study protocol and procedure will be at the bedside throughout the sampling period and will be monitoring for study compliance as per protocol. Data collection is completed by the research team in real time to ensure accuracy and negate the chance of missed data points. A data collection sheet will be completed for all samples collected including time of collection. Nebulization start and stop time is recorded. Medication dose will be calculated and checked by 2 competent clinical personnel at least one of whom will be a study team member. The template medication order will be used to ensure accuracy and consistency across all patients. Clear instructions are provided in the bedside resources for the study team to use that outline sample collection procedure and handling. Study team are highly experienced in these kind of studies and understand the importance of timeliness, correct sample handing and processing and adherence to protocol.
A monitoring plan has been established for the study, including a Safety Monitoring Committee (SMC). Protocol adherence will be easily monitored s this is a single site study and the study team will be directly involved in each case. The study will be conducted in accordance with ethical principles consistent with the Declaration of Helsinki, and all relevant national and local guidelines on the ethical conduct of research. The Research team will include experienced research coordinators, intensive care specialists, all with Good Clinical practice (GCP) certification who will have oversight of all study activities and protocol adherence.
All data will be directly entered from the source into the REDCap electronic database. the database has the capacity to run validity checks and logic queries to minimise errors. the study monitor will perform 100% source data verification (SDV) for the first patient recruited and 100% SDV on all patients for informed consent in accordance with HREC approval, reportable adverse events as per protocol, clinical outcomes and protocol deviations.
Query!
Intervention code [1]
330918
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
341241
0
To evaluate the plasma pharmacokinetics of single dose ketamine in post-operative cardiac surgery patients in the ICU.
Query!
Assessment method [1]
341241
0
The following PK parameters will be examined - area under the concentration-time curve extrapolated to infinity (AUC(0-80)), peak plasma concentration (Cmax), the time to reach Cmax (Tmax), and the mean residence time (MRT (0-t)). the terminal half-life (T1/2) and the clearance rate (CL) will be obtained. The plasma samples will be analysed for drug concentration using validated high-performance liquid chromatography (HPLC) method on a Nexera2 UHPLC system coupled to a 8050 triple quadruple mass spectrometer (Shimadzu Corporation, Kyoto, Japan). Bioanalysis will be conducted in accordance with the U.S.A FDA guidance for industry on bioanalysis at the Central Bioanalysis Laboratory at the University of Queensland.
Query!
Timepoint [1]
341241
0
Plasma samples will be collected over a two hour sampling window where T=0 is the commencement of nebulization of the study frug. A total of 8 samples will be collected. T0, T+5, +10, +15, +30, +60, +90, +120 minutes.
Query!
Primary outcome [2]
341242
0
Urine Creatine Clearance (CrCL)
Query!
Assessment method [2]
341242
0
Urine CrCL will be analysed by the Queensland Pathology laboratory as per standard clinical practice.
Query!
Timepoint [2]
341242
0
A two hour urine CrCL will be collected on the day of sampling where commencement of sample is the start time of nebulization.
Query!
Secondary outcome [1]
446900
0
Safety
Query!
Assessment method [1]
446900
0
1. vital signs of heat rate, blood pressure and oxygen saturation will be continuously monitored via a Philips Monitor as per standard ICU management. 2. Glasgow Coma Score (GCS) is measured using an internationally validated clinical tool that measures a person's level of consciousness. 3. Continuous monitoring of heart rate, blood pressure and oxygen saturation as per standard ICU management will be used by the trained, qualified research team who perform the study related procedures and the treating medical and nursing team to monitor for adverse events of special interest. These events are listed below a) to e) a) bronchospasm defined as sudden constriction of the muscles in the wall of the bronchioles and as assessed by a clinician or member of the study team. b) hypoxia defined as oxygen saturation less than 90% c) hypotension defined as systolic blood pressure less than 90 mmHg. d) bradycardia as defined as heart rate less than 60 beats per minute. e) GCS drop of 2 or more points compared to pre-nebulization score. SMC will identify any serious safety concerns that emerge during the study by regular monitoring of the study progress.
Query!
Timepoint [1]
446900
0
Monitoring for adverse events will occur during the study sampling period and up to 4 hours after end of study drug nebulisation.
Query!
Secondary outcome [2]
446903
0
Feasibility of a large randomized controlled trial to provide effective analgesia as an adjunct for conventional therapy for pain management in this patient population.
Query!
Assessment method [2]
446903
0
Composite secondary outcome. Pain will be evaluated using 1. The validated Numeric Pain Rating Scale (NPRS) which has a scoring domain of 0 (no pain) to 10 (highest conceivable pain). 2. Requirement for break-through analgesia (oral or intravenous) during the two hour sampling period. Research team will be present at the bedside throughout the entire sampling period and will capture this in real time through observation of patient clinical cares and engagement with patient and treating clinicians. If the patient requires any additional analgesia during the sampling period from when nebulisation commences until 2 hours after nebulisation this information will be collected. The generic name, dose and route of the medication will be recorded on the data sheets at the bedside on each occurrence. 3. Richmond Agitation Severity Score (RASS).
Query!
Timepoint [2]
446903
0
Pain monitoring 1. NPRS and RASS assessment at T=0 (baseline predosing), 30 min, 60 min, end of study (T=120 min 2 hour post nebulization). 2. Break through analgesia during the two hour sampling period post-nebulization.
Query!
Eligibility
Key inclusion criteria
Post-operative cardiac surgery patient in the intensive care unit willbe considered if they meet the following criteria:
1. Adult greater than or equal to 18 years
2. Has an arterial or central venous line insitu
3. Requiring analgesia as per treating team
4. Able to provide consent to participate
5. Able to inhale nebulized medications
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. suspected or known hypersensitivity to ketamine
2. already receiving ketamine for analgesia
3. severe chronic lung disease
4. systolic blood pressure less than 11 mmHg
5. high oxygen requirement FiO2 greater than or equal to 0.4
6. cardiac dysrhythmia
7. receiving renal replacement therapy
8. liver failure or Child-Pugh C liver cirrhosis
9. pregnant or lactating patients
10. history of significant mental health disorder or psychological distress as assessed by the PI that will impact consent and/or prevent participation in the study
11. delirium
12. previous enrolment in the NIKI-C study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
The sample size for the study is a minimum of 20 patients. The sample size is based on data from similar studies and will provide a power of 80% and is expected to obtain robust population PK [parameter predictions in this patient population, which demonstrates high PK variability.
Continuous variables will be assessed for normality and expressed as means ± SD or medians ± IQR and categorical variables will be expressed as proportions.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
14/07/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
30/12/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2026
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
27847
0
The Prince Charles Hospital - Chermside
Query!
Recruitment postcode(s) [1]
44042
0
4032 - Chermside
Query!
Funding & Sponsors
Funding source category [1]
318825
0
University
Query!
Name [1]
318825
0
University of Queensland Research Fellowship
Query!
Address [1]
318825
0
Query!
Country [1]
318825
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Queensland
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
321304
0
None
Query!
Name [1]
321304
0
Query!
Address [1]
321304
0
Query!
Country [1]
321304
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
317442
0
Metro North Health Human Research Ethics Committee B
Query!
Ethics committee address [1]
317442
0
https://metronorth.health.qld.gov.au/research/ethics-and-governance/human-research-ethics-committee
Query!
Ethics committee country [1]
317442
0
Australia
Query!
Date submitted for ethics approval [1]
317442
0
31/01/2024
Query!
Approval date [1]
317442
0
03/06/2024
Query!
Ethics approval number [1]
317442
0
HREC/2024/MNHB/105595
Query!
Summary
Brief summary
Study Title: The NIKI-C Study - A study of pharmacokinetics of nebulized ketamine in post-operative cardiac surgery patients in intensive care unit: A phase 2, single site, prospective, interventional, open-label pharmacokinetic study. A minimum of 20 patients will be consented and enrolled to receive a single dose of nebulized ketamine 0.75mg/kg (ideal body weight). Over a 2 hour sampling period 8 blood and 2 urine samples will be collected. Assessments will be conducted to report feasibility, pain, tolerance, concomitant sedatives and analgesia as well as monitoring for study specific adverse events. The hypothesis of the study are that 1. Plasma blood levels of nebulized ketamine in ICU post-operative cardiac surgery patients is adequate to provide analgesia. 2. Nebulized ketamine is not associated with any serious adverse events in the ICU post-operative cardiac surgery patients.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
141042
0
Dr Kiran Shekar
Query!
Address
141042
0
Intensive Care Department, The Prince Charles Hospital, 627 Rode Road, Chermside. QLD 4032
Query!
Country
141042
0
Australia
Query!
Phone
141042
0
+61 7 3139 5922
Query!
Fax
141042
0
Query!
Email
141042
0
[email protected]
Query!
Contact person for public queries
Name
141043
0
Kiran Shekar
Query!
Address
141043
0
Intensive Care Department, The Prince Charles Hospital, 627 Rode Road, Chermside. QLD 4032
Query!
Country
141043
0
Australia
Query!
Phone
141043
0
+61 7 3139 5922
Query!
Fax
141043
0
Query!
Email
141043
0
[email protected]
Query!
Contact person for scientific queries
Name
141044
0
Jayesh Dhanani
Query!
Address
141044
0
ICU Research, Level 3 Ned Hanlon Building Butterfield Street Herston QLD 4029
Query!
Country
141044
0
Australia
Query!
Phone
141044
0
+61 7 3646 8897
Query!
Fax
141044
0
Query!
Email
141044
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF